+1.224.938.9523

HUMAN AMYLOID IMAGING CONFERENCE

The 16th edition of the HAI will be held in Miami, FL on January 17-19, 2024.

2023 PROGRAM

The event was held at the James L. Knight Center located downtown Miami, FL at 400 SE 2nd Ave.  

WEDNESDAY, JANUARY 11

7:30 AMCheck-in and Breakfast
8:15 AMWelcome Notes; IntroductionsKeith Johnson, MD, Massachusetts General Hospital
8:25 AMAnnouncement: Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET): Defining the future of Alzheimer's treatment, imaging and careMaria Carrillo, PhD, Alzheimer's Association
8:30 AMSESSION I: TRACER DEVELOPMENT AND EVALUATIONCHAIRS: Julie Price, PhD, Massachusetts General Hospital
Chet Mathis, PhD, University of Pittsburgh
8:30 AMIntroductionChairs
8:35 AMAdvances towards the identification of an α-synuclein Positron Emission Tomography radioligand for the diagnosis of Parkinson’s diseaseIdriss Bennacef, PhD, Merck & Co.
8:50 AMDiscovery of [18F]ACI-12589, a novel and promising PET-tracer for a-synucleinFrancesca Capotosti, PhD, AC Immune
9:05 AMDiscovery and preclinical evaluation of two novel PET tracers for imaging non-AD tauopathiesMarc Skaddan, PhD, AbbVie
9:20 AMIn vivo head-to-head comparison of [18F]GTP1, [18F]PI2620, and [18F]MK6240 in Alzheimer’s diseaseMatteo Tonietto, PhD, F. Hoffman-La Roche
9:35 AMDIDACTIC LECTURE: PET IMAGING BEYOND AMYLOID WITH ANTIBODY-BASED RADIOLIGANDS Dag Sehlin, PhD, Uppsala University
10:00 AMSession I Discussion
10:30 AMP1A- POSTER SESSION/BREAK
11:15 AMSESSION II: TECHNICAL ADVANCES FOR CLINICAL APPLICATIONSCHAIRS: Suzanne Baker, PhD, Lawrence Berkeley National Laboratory
Bradley Christian, PhD, University of Wisconsin, Madison
11:15 AMIntroductionChairs
11:20 AMMinimizing sample sizes for trials using MK-6240 outcomes: impact of processing method and choice of reference and target tissuesJ. Alex Becker, PhD, Massachusetts General Hospital
11:35 AMInferring full ATN status from tau-PET using deep learningNicolai Franzmeier, PhD, LMU Munich
11:50 AMLongitudinal modelling of tau transport and production dynamics in the human brainPavan Chaggar, PhD, University of Oxford
12:05 PMConnectivity- versus gradient-based approaches to predict regional tau-PET across Alzheimer’s disease variantsNick Corriveau-Lecavalier, PhD, Mayo Clinic, Rochester
12:20 PMMeasuring tau in the basal forebrain: a comparison of MK6240 and flortaucipirTheresa Harrison, PhD, University of California, Berkeley
12:35 PMSession II Discussion
1:00 PMLUNCH
2:00 PMKEYNOTE: SYNAPTIC PATHOLOGY IN NEURODEGENERATIONThomas Montine, MD, Stanford University
2:30 PMKeynote Discussion
2:45 PMSESSION III: THRESHOLDS, VISUAL READS AND REAL WORLD IMAGINGCHAIRS: Pedro Rosa-Neto, MD, PhD, McGill University
Ansel Hillmer, PhD, Yale School of Medicine
2:45 PMIntroductionChairs
2:50 PMBiostatistical estimation of tau threshold hallmarks (BETTH) for tau imaging studiesAlexandra Gogola, PhD, University of Pittsburgh School of Medicine
3:05 PMVisual read of [18F]florquinitau PET that includes and extends beyond the mesial temporal lobe is associated with amyloid positivity and retrospective cognitive decline in an AD risk-enriched cohortSterling Johnson, PhD, University of Wisconsin School of Medicine and Public Health
3:20 PMHead-to-head comparison of tau and amyloid PET visual reads for differential diagnosis: An international, multi-center studyDavid Soleimani-Meigooni, PhD, University of California, San Francisco
3:35 PMQuantitative analysis of 8,895 real-world amyloid Positron Emission Tomography (PET) scans from the Imaging Dementia–Evidence for Amyloid Scanning (IDEAS) studyEhud Zeltzer, MD, University of California, San Francisco
3:50 PMSession III Discussion
4:15 PMP1B: POSTER SESSION/BREAK
5:00 PMSESSION IV: NON-AD AND CO-PATHOLOGIESCHAIRS: Milos Ikonomovic, MD, University of Pittsburgh
Melissa Murray, PhD, Mayo Clinic, Jacksonville
5:00 PMIntroductionChairs
5:05 PMTau burden evaluation by [18F] Flortaucipir PET and quantitative tau neuropathology in Alzheimer's disease and non-Alzheimer’s tauopathiesRodolfo Gatto, PhD, Mayo Clinic, Rochester
5:20 PMPathologic correlations of [18F]-Flortaucipir imaging in non-Alzheimer corticobasal syndromeCinthya Aguero, MD, MassGeneral Institute for Neurodegenerative Disease
5:35 PMUnveiling the neurobiological basis of F18-flortaucipir in different tauopathies using voxel-to-voxel histology to PET comparisons: the role of p-tau, iron and MAOBYuheng Chen, PhD, University of California, San Francisco
5:50 PMAssociation of FDG-PET with co-pathologies in autopsy-proven ADMarianne Chapleau, PhD, University of California, San Francisco
6:05 PMSession IV Discussion
6:30 PMRECEPTION
9:00 PMDAY 1 ENDS

Thursday, JANUARY 12

7:30 AMBreakfast
8:30 AMSESSION V: AD NEUROPATHOLOGYCHAIRS: Teresa Gomez-Isla, MD, PhD, Massachusetts General Hospital
Laetitia Lemoine, PhD, Karolinska Institutet
8:30 AMIntroductionChairs
8:35 AMSpecific associations between plasma biomarkers and post-mortem amyloid plaque and neurofibrillary tau tangle loadsGemma Salvado, PhD, Lund University
8:50 AMIntersection of amyloid-β and tau brain pathology influences plasma phosphorylated tau levelsMelissa Murray, PhD, Mayo Clinic, Jacksonville
9:05 AMTangle maturity markers associate with tau PET and cognitive measures in hippocampusChristina Moloney, PhD, Mayo Clinic, Jacksonville
9:20 AMPostmortem validation of 18F-MK-6240 PET using autoradiography and in-vitro binding combined with antibody-based assays in frozen brains from two autopsy casesTobey Betthauser, PhD, University of Wisconsin-Madison
9:35 AMSession V Discussion
10:00 AMP2A: POSTER SESSION/BREAK
10:45 AMSESSION VI: HETEROGENEITY IN THE AD CASCADECHAIRS: Heidi Jacobs, PhD, Massachusetts General Hospital
Susan Landau, PhD, University of California, Berkeley
10:45 AMIntroductionChairs
10:50 AMLongitudinal increases in tau emerge alongside early amyloid change in Down syndromeMatt Zammit, PhD, University of Wisconsin-Madison
11:05 AMCross-sectional and longitudinal associations between amyloid- and tau-PET in early-onset Alzheimer’s disease: update from the LEADS studyNidhi Mundada, PhD, University of California, San Francisco
11:20 AMAmyloid PET burden predicts longitudinal cognitive trajectories in a heterogeneous ADRD cohortKyan Younes, PhD, Stanford University
11:35 AMVariations in gamma-secretase function across PSEN1 pathogenic variants strongly predict the clinical, cognitive, and biomarker progression of autosomal dominant Alzheimer’s disease (MGH, DIAN)Stephanie Schultz, PhD, Massachusetts General Hospital
11:50 AMSession VI Discussion
12:15 PMLUNCH
1:15 PMSESSION VII: TAU PET AND MRI: MULTIMODALITY INSIGHTSCHAIRS: Annie Cohen, PhD, University of Pittsburgh
Beth Mormino, PhD, Stanford University
1:15 PMIntroductionChairs
1:20 PMMapping tau accumulation to the functional and structural organization of the brain in Alzheimer’s diseaseJulie Ottoy, PhD, University of Toronto
1:35 PMBaseline tau PET shows stronger associations with cognitive and behavioral changes over time than cortical thicknessEllen Singleton, PhD, Lund University
1:50 PMA central role of Locus Coeruleus in the initial spatiotemporal progression of tau and its contribution to cognition (MGH) Heidi Jacobs, PhD, Massachusetts General Hospital/Harvard Medical School
2:05 PMTau propagation in the brain olfactory circuits contributes to smell perception changes in agingIbai Diez, PhD, Massachusetts General Hospital/Harvard Medical School
2:20 PMMedial temporal lobe subregional microstructure measured with ultra-high resolution diffusion imaging as a biomarker for early tau pathology and memory impairment (UCI)Jenna Adams, PhD, University of California, Irvine
2:35 PMSession VII Discussion
3:00 PMKEYNOTE: ON MAKING NEUROIMAGING STUDIES MORE EQUITABLE, INCLUSIVE AND RELEVANTMonica Rivera Mindt, PhD, Fordham University
3:30 PMKeynote Discussion
3:45 PMP2B: POSTER SESSION/BREAK
4:30 PMSESSION VIII: LIFESTYLE AND LIVED EXPERIENCESCHAIRS: Gil Rabinovici, MD, University of California, San Francisco
Tobey Betthauser, PhD, University of Wisconsin-Madison
4:30 PMIntroductionChairs
4:35 PMAfrican American racialization modifies the association between apolipoprotein-E4 and amyloid depositionSarah Royse, PhD, University of Pittsburgh
4:50 PMCardiovascular risk and AD biomarkers in unimpaired older adults: A comparison of U.S. POINTER and ADNISusan Landau, PhD, University of California, Berkeley
5:05 PMAssociation between mid-life social factors and estimated late life amyloid burden: the Atherosclerosis Risk in Communities (ARIC)-PET studyRenee Groechel, PhD, NINDS
5:20 PMSession VIII Discussion
5:45 PMRECEPTION
8:00 PMDAY 2 ENDS

Friday, JANUARY 13

8:00 AMBreakfast
8:00 AMNEW!Breakfast with a Mentor
9:00 AMSESSION IX: LONGITUDINAL CHANGES IN TAU AND AMYLOID MARKERSCHAIRS: Keith Johnson, MD Massachusetts General Hospital
William Jagust, MD, University of California, Berkeley
9:00 AMIntroductionChairs
9:05 AMLongitudinal tau accumulation is associated with faster memory decline in typical aging and preclinical Alzheimer’s diseaseCorrina Fonseca, PhD, University of California, Berkeley
9:20 AMThe use of plasma markers to predict tau accumulation in a stage-specific mannerCécile Tissot, PhD, McGill University
9:35 AMTemporal dynamics of plasma pTau217 and amyloid PET in preclinical ADKarly Cody, PhD, University of Wisconsin-Madison
9:50 AMLongitudinal changes in Alzheimer’s disease-related plasma biomarkers in relation to changes in PiB PET measures of brain amyloidMurat Bilgel, PhD, NIA
10:05 AMLongitudinal bidirectional associations between sleep and Alzheimer’s pathology in at-risk cognitively unimpaired older adultsBery Mohammediyan, MSc, McGill University
10:20 AMSession IX Discussion
10:45 AMP3A: POSTER SESSION/BREAK
11:30 AMSESSION X: FLUID BIOMARKERS IN ADCHAIRS: Henrik Zetterberg, MD, PhD, University of Gothenburg
Donna Wilcox, PhD, University of Kentucky College of Medicine
11:30 AMIntroductionChairs
11:35 AMPlasma p-tau217 ratios associated with amyloid and tau PET measures in preclinical AD: Findings from the AHEAD 3-45 Study screening dataReisa Sperling, MD, MGH/Harvard Medical School
11:50 AMPlasma biomarkers as stand-alone tests to rule out Alzheimer's diseaseJoseph Therriault, PhD, McGill University
12:05 PMComparative performance of three plasma Aβ42/Aβ40 and two plasma p-tau181 assays versus amyloid-PET imaging statusAlicia Algeciras-Schimnich, PhD, Mayo Clinic, Rochester
12:20 PMPrognostic utility of plasma p217+tau vs amyloid and tau PET in the Alzheimer continuumAzadeh Feizpour, PhD, Austin Health
12:35 PMAssociations of blood biomarkers with early-onset Alzheimer’s disease pathologyPaige Logan, PhD, Indiana University School of Medicine
12:50 PMAssociations between amyloid PET, CSF pTau, and plasma biomarkers in memory clinic patientsMarina Bluma, PhD, Karolinska University
1:05 PMLUNCH
2:05 PMSession X Discussion
2:30 PMKEYNOTE: BIOFLUIDS AND IMAGING: TWO SIDES OF THE SAME COINThomas Karikari, PhD, University of Pittsburgh School of Medicine
3:00 PMKeynote Discussion
3:15 PMP3B: POSTER SESSION/BREAK
4:00 PMAWARDS
4:15 PMSESSION XI: PLASMA WITH OTHER MODALITIESCHAIR: Thomas Karikari, PhD, University of Pittsburgh
Suzanne Schindler, MD, PhD, Washington University
4:15 PMIntroductionChairs
4:20 PMPlasma biomarkers associated with cortical brain structure and multi-domain cognition in Alzheimer’s disease and Parkinson’s diseaseGillian Coughlan, PhD, Massachusetts General Hospital
4:35 PMRelationships of blood insulin with brain structures and plasma Aβ42 to Aβ40 ratio in a multi-ethnic cohort of older adultsBrandon Hall, MSc, University of Southern California
4:50 PMUnique biological pathways associated with plasma ptau species and AD PET: an imaging-transcriptomic studyMin Su Kang, PhD, Sunnybrook Research Institute
5:05 PMSession XI Discussion
5:30 PMCONCLUDING REMARKSTeresa Gomez-Isla, MD, PhD, Massachusetts General Hospital
Thomas Karikari, PhD, University of Pittsburgh
Beth Mormino, PhD, Stanford University
Julie Price, PhD, Massachusetts General Hospital
5:35 PMCONFERENCE ENDS
REGISTRATION IS NOW CLOSED